Form 4: Lexicon Pharmaceuticals CFO Jeffrey Wade Reports Stock Transactions
SEC Form 4 Filing
Lexicon Pharmaceuticals' CFO, Jeffrey Wade, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Summary
- On February 28, 2024, Jeffrey L. Wade, the President and CFO of Lexicon Pharmaceuticals, reported transactions involving common stock and restricted stock units.
- These transactions involved the vesting of restricted stock units and the subsequent withholding of shares by the company to cover tax obligations.
- Specifically, 11,177, 37,274 and 49,113 restricted stock units vested, converting into common stock.
- The company withheld 37,691 shares at a price of $2.62 to satisfy tax obligations.
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard executive compensation practices. It doesn't indicate positive or negative performance for the company.
Industry Context
This is a routine filing related to executive compensation and is common for publicly traded companies.
Stakeholder Impact
- The transactions have a minor impact on shareholders due to the change in beneficial ownership of shares.
- Employees holding restricted stock units are affected by the vesting schedule and tax implications.
Key Dates
| Date | Description |
|---|---|
| 02/28/2024 | Date of earliest transaction: vesting of restricted stock units and tax withholding. |
| 02/29/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.